Welcoming Dr. Max Horlbeck as Director of the Roya Kabuki Program
Since 2017, families affected by Kabuki syndrome have turned to the Roya Kabuki Program at Boston Children’s Hospital for specialized clinical expertise, compassionate care, and opportunities to contribute to research.
As the program enters a new chapter, we are grateful to celebrate the extraordinary contributions of Dr. Olaf Bodamer while welcoming new members of the Roya team.
After 9 years of leading the Roya Kabuki Program, Dr. Olaf Bodamer is transitioning leadership of the program to Dr. Max Horlbeck, the newly appointed Director of the Roya Kabuki Program. Dr. Bodamer will continue to see patients in the clinic, bringing his decades of experience and deep knowledge of Kabuki syndrome to the families he serves.
Dr. Bodamer has been a champion for both families and research. Over the years, he has helped advance several research initiatives, including work supported by the Kabuki Syndrome Foundation. His commitment to understanding Kabuki syndrome and improving care has helped lay important groundwork for the clinical and research efforts continuing today.
We are deeply grateful to Dr. Bodamer for his years of dedication to the Kabuki syndrome community and for the expertise, collaboration, and leadership he has brought to the Roya Kabuki Program. His contributions have helped shape a program that continues to be a key resource for families and an important part of the broader Kabuki syndrome research community.
Welcoming Dr. Max Horlbeck
We are excited to welcome Dr. Max Horlbeck as the new Director of the Roya Kabuki Program.
Dr. Horlbeck is a clinical geneticist and principal investigator at Boston Children’s Hospital and an Assistant Professor of Genetics at Harvard Medical School. His clinical and research work focuses on genetic disorders of chromatin biology, an area of expertise that is particularly relevant to understanding Kabuki syndrome.
He earned his MD and PhD from the University of California, San Francisco. In his graduate work with Jonathan Weissman, he developed CRISPR interference and activation technologies. Dr. Horlbeck went on to train in Pediatrics and Clinical Genetics at Boston Children’s Hospital and completed postdoctoral research with Jason Buenrostro at Harvard University and the Broad Institute. His research has included developing new approaches to understand how DNA regulatory elements are organized using chromatin accessibility measurements.
Today, his lab uses state-of-the-art genetic and molecular tools to better understand the mechanisms underlying chromatin disorders and identify potential paths toward treatment. He also serves as co-director of the EpiChroma Clinic, which specializes in these disorders. A chromatin disorder, also known as a chromatinopathy, is a genetic condition that affects chromatin, the system that packages DNA and helps regulate which genes are turned on or off. Kabuki syndrome is considered a chromatinopathy because changes in the KMT2D or KDM6A genes can disrupt chromatin regulation, affecting how genes are expressed throughout the body.
As the new Director of the Roya Kabuki Program, Dr. Horlbeck brings deep scientific expertise, clinical experience, and a strong interest in translating discoveries in chromatin biology into a better understanding of Kabuki syndrome.
We look forward to supporting Dr. Horlbeck as he takes on this new role and to seeing how his expertise and enthusiasm help shape the next chapter of the Roya Kabuki Program.
Continuing a Strong Clinical Team
The Roya Kabuki Program’s clinical expertise is multidisciplinary and brings together specialists with experience across the many areas of health and development that can be affected by Kabuki syndrome. To increase patient access, Genetics care for Kabuki syndrome will be provided by Dr. Horlbeck and Dr. Bodamer, as well as Dr. Aya Abu-El-Haija, a geneticist who has long been a member of the Roya Kabuki Program, and Dr. Anne O’Donnell-Luria. Dr. O’Donnell-Luria serves as Co-Director of the EpiChroma Clinic and will work closely with the Roya team. Her expertise and connections within the EpiChroma Clinic open new possibilities for collaborations with other chromatinopathies, conditions also known as Kabuki syndrome’s “rare disease cousins.” She is also a Principal Investigator at the Broad Institute and leader in rare disease research and gene discovery. By bringing experts and communities studying related conditions together, these collaborations can help accelerate research and improve clinical care for people with Kabuki syndrome and beyond.
Team members from multiple specialties, known as Kabuki Champions, are involved in providing expertise, sharing knowledge, and supporting a coordinated approach to care. These Champions include:
- Dr. Tina Yee, Immunology,
- Dr. Rachael Grace, Hematology
- Dr. Ben Goodlette, who brings expertise in Neuropsychology,
- Drs. Margaret Kenna and Elliot Shearer, Ear, Nose, Throat (Otorhinolaryngology)
- as well as other clinicians who contribute their specialized knowledge to improve understanding and care for people with Kabuki syndrome.
We also want to recognize and thank the many members of the Roya team who have supported individuals and families over the years, including Natalie Formica, Rachel Gottlieb, Tara Daly, and others who have thoughtfully helped families navigate care and research at Boston Children’s Hospital.
Their work reflects something that is central to our mission: advancing research is essential, but improving the lives of people with Kabuki syndrome also requires knowledgeable, compassionate clinical care and support for families along the way.
We are grateful to everyone who has contributed to creating a clinical program where families can find specialized expertise and feel supported throughout their Kabuki syndrome journey.
Welcoming Callie to the Roya Kabuki Program
We are also excited to welcome Callie Sullivan, MS, CGC (Certified Genetic Counselor) to the Roya team as its Program Coordinator.
For families connecting with the Roya Kabuki Program, Callie will be a critical first point of contact. She can help answer questions about referrals, insurance, virtual visits, and appointments, as well as help coordinate visits across multiple specialties. For families who are interested in research, Callie can also help connect them with research opportunities.
Callie earned her Master’s degree in Genetic Counseling at Mass General Brigham University of Health Professions (formerly MGH Institute of Health Professions) in Boston, Massachusetts. During her clinical training, she worked with patients seeking genetic counseling in prenatal, pediatric, and cancer genetics clinics at Mass General Brigham hospitals. She also conducted a capstone research project exploring prenatal genetic counselors’ perspectives of counseling on digenic conditions that appear on carrier screening, furthering her interest in clinical research. Her first exposure to the rare disease community was during a rotation with the National Tay-Sachs and Allied Diseases Association, where she grew passionate about advocating for rare disease families.
In addition to her role as the Program Coordinator for the Roya Kabuki Program, Callie will also serve as a data curator for Kabuki INSIGHTS, the Kabuki syndrome research registry and data hub. In this role, she will use her expertise to curate genetic reports submitted to the registry, helping ensure that the information is accurate, consistent, and standardized for research use.
Whether a family is visiting Boston in person or connecting virtually, having a dedicated team member to help navigate the process can make accessing specialized Kabuki syndrome care easier.
To learn more about the Roya Kabuki Program or schedule an appointment email kabuki@childrens.harvard.edu or call 617-355-1412.
Founded by Parents: The Roya Kabuki Program
The story of the Roya Kabuki Program began with two parents who wanted to change what was possible for their daughter and for families affected by Kabuki syndrome.
In the summer of 2017, Leila and Edoardo Zegna, Roya’s parents, launched the Roya Kabuki Program at Boston Children’s Hospital with an ambitious goal: to advance research toward treatments for Kabuki syndrome.
Their vision was not only to accelerate Kabuki syndrome research, but also to build knowledge and research approaches that could have implications far beyond Kabuki syndrome. Leila and Edoardo continue to champion this vision; they have served on the Kabuki Syndrome Foundation’s Board of Directors since 2021 and remain active supporters of Kabuki syndrome research and strategy.
Today, the Kabuki Syndrome Foundation and our supporters help make their vision possible by funding a portion of the ongoing work at the Roya Kabuki Program at Boston Children’s Hospital. This investment helps sustain the program’s clinical and research efforts, bringing together specialized expertise to improve care for families while advancing research toward future treatments.
We are proud to partner with Leila and Edoardo, the Roya team, researchers, clinicians, families, and supporters who share a commitment to moving Kabuki syndrome research forward.
Together, we are working to create a future in which scientific discoveries can translate into better understanding, improved care, and ultimately treatment options for people with Kabuki syndrome.
KSF-Funded Research at the Roya Kabuki Program
The Roya Kabuki Program has been an important partner in our efforts to accelerate Kabuki syndrome treatment research. On location at Boston Children’s Hospital, families and researchers have contributed to the Kabuki Syndrome Outcome Measures and Biomarkers Consortium (KSOC), a collaborative effort designed to identify and validate tools that can help researchers better understand Kabuki syndrome and prepare for future clinical trials. While KSOC Cohort 1 is no longer enrolling participants, data collection is complete. The research team is now reviewing the findings and preparing for the next steps, including publication. The next chapter of KSOC, Cohort 2, is expected to begin recruitment in 2027, continuing this important work to advance outcome measures and biomarkers for Kabuki syndrome research.
Research at Roya has also contributed to efforts to identify existing medicines that may have potential for Kabuki syndrome. Drug repurposing offers an important opportunity in rare disease research: rather than beginning with a completely new drug, researchers can investigate medications that have already been developed or approved for other conditions to determine whether they may treat symptoms of Kabuki syndrome. In 2025, KSF awarded $110,000 to Dr. Bodamer for this work. Dr. Horlbeck received an additional $20,000 in 2026 to continue this effort.
This progress takes collaboration, expertise, persistence, and investment. We are proud that KSF and our supporters make this work possible.
Read Our Latest Research Updates
Looking Ahead Together
The Roya Kabuki Program has been built over years of dedication from families, clinicians, researchers, staff, and supporters who believe that people with Kabuki syndrome deserve better answers and better treatments.
We are deeply thankful to Dr. Bodamer for his many years of commitment to the Kabuki syndrome community and to the research that will continue to shape the future of the field.
We are equally excited to welcome Dr. Horlbeck and Callie to the Roya team and to continue supporting the Roya Kabuki Program.
With experienced clinicians continuing to care for families and research moving forward, we believe the future of collaborations with the Roya Kabuki Program and Kabuki Syndrome Foundation is an exciting one.
And, as always, families are at the heart of this work.
If you or your family are interested in learning more about the Roya Kabuki Program, connecting with the clinical team, or exploring opportunities to participate in research, we encourage you to reach out to the Roya team at kabuki@childrens.harvard.edu.
Together, we can continue improving care today and advancing treatments for tomorrow.